Alkermes plc. ALKS
4 targets with a reported result
Releases of the last 3 yearsThe numbers ALKS said it expected, in its earnings releases, next to what it then reported for the same period.
Target by target
Each target, with the sentence it came from · release and 10-Q or 10-K
| Target | What the company said | Reported | Result | |
|---|---|---|---|---|
| EBITDA (company-defined) Fiscal 2026 |
Given $370.00M to $410.00M release Feb 25, 2026
Kept $370.00M to $410.00M release May 5, 2026
Kept $370.00M to $410.00M release Jul 28, 2026
|
– | No standard number | |
The company's words(In millions) 2026 Expectations … Adjusted EBITDA $370 – $410 release Feb 25, 2026 Updated 2026 Previous 2026 Expectations(provided Expectations(provided May 5, (In millions) Feb. 25, 2026) 2026) … Adjusted EBITDA e $370 – $410 release May 5, 2026 Previous 2026 Updated 2026 Expectations(provided Expectations(provided May 5, July 28, (In millions) 2026) 2026) … Adjusted EBITDA f $370 – $410 release Jul 28, 2026 | ||||
| Revenue Fiscal 2026 |
Given $1.73B to $1.84B release Feb 25, 2026
Kept $1.73B to $1.84B release May 5, 2026
Kept $1.73B to $1.84B release Jul 28, 2026
|
– | Not reported yet | |
The company's words(In millions) 2026 Expectations … Total Revenues $1,730 – $1,840 release Feb 25, 2026 Updated 2026 Previous 2026 Expectations(provided Expectations(provided May 5, (In millions) Feb. 25, 2026) 2026) … Total Revenues $1,730 – $1,840 release May 5, 2026 Previous 2026 Updated 2026 Expectations(provided Expectations(provided May 5, July 28, (In millions) 2026) 2026) … Total Revenues $1,730 – $1,840 release Jul 28, 2026 | ||||
| EBITDA (company-defined) Fiscal 2025 (ended Dec 31, 2025) |
Given $215.00M to $245.00M release Feb 12, 2025
Raised $270.00M to $290.00M release Oct 28, 2025
|
– | No standard number | |
The company's wordsIn millions 2025 Expectations … EBITDA $215 – $245 release Feb 12, 2025 Previous 2025 Updated 2025 Expectations(provided Expectations(provided (In millions) Feb. 12, 2025) Oct. 28, 2025) … EBITDA b $270 – $290 release Oct 28, 2025 | ||||
| Net income Fiscal 2025 (ended Dec 31, 2025) |
Given $175.00M to $205.00M release Feb 12, 2025
Raised $230.00M to $250.00M release Oct 28, 2025
|
$241.66M 10-K filed 2026-02-25 |
Within the range | |
The company's wordsIn millions 2025 Expectations … GAAP Net Income a $175 – $205 release Feb 12, 2025 Previous 2025 Updated 2025 Expectations(provided Expectations(provided (In millions) Feb. 12, 2025) Oct. 28, 2025) … GAAP Net Income a $230 – $250 release Oct 28, 2025 | ||||
| Revenue Fiscal 2025 (ended Dec 31, 2025) |
Given $1.34B to $1.43B release Feb 12, 2025
Lowered $265.00M to $275.00M release Oct 22, 2025
Raised $1.43B to $1.49B release Oct 28, 2025
|
$1.48B 10-K filed 2026-02-25 |
Within the range | |
The company's wordsIn millions 2025 Expectations … Total Revenues $1,340 – $1,430 release Feb 12, 2025 With net revenues of $265 – $275 million expected in 2025 and an estimated population of >50,000 oxybate- eligible narcolepsy patients in the United States, LUMRYZ ™has been on a robust growth trajectory, with significant opportunity for growth ahead. release Oct 22, 2025 Previous 2025 Updated 2025 Expectations(provided Expectations(provided (In millions) Feb. 12, 2025) Oct. 28, 2025) … Total Revenues $1,430 – $1,490 release Oct 28, 2025 | ||||
| EBITDA (company-defined) Fiscal 2024 (ended Dec 31, 2024) |
Given $445.00M to $485.00M release Feb 15, 2024
|
– | No standard number | |
The company's wordsIn millions 2024 Expectations … EBITDA $445 – $485 release Feb 15, 2024 | ||||
| Net income Fiscal 2024 (ended Dec 31, 2024) |
Given $350.00M to $390.00M release Feb 15, 2024
|
$367.07M 10-K filed 2025-02-12 |
Within the range | |
The company's wordsIn millions 2024 Expectations … GAAP Net Income b $350 – $390 release Feb 15, 2024 | ||||
| Net income (company-defined) Fiscal 2024 (ended Dec 31, 2024) |
Given $465.00M to $505.00M release Feb 15, 2024
|
– | No standard number | |
The company's wordsIn millions 2024 Expectations … Non-GAAP Net Income b $465 – $505 release Feb 15, 2024 | ||||
| Revenue Fiscal 2024 (ended Dec 31, 2024) |
Given $1.50B to $1.60B release Feb 15, 2024
|
$1.56B 10-K filed 2025-02-12 |
Within the range | |
The company's wordsIn millions 2024 Expectations … Total Revenues a $1,500 – $1,600 release Feb 15, 2024 | ||||
Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (15 releases since 2024-02-15), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.
Sources
The outlook sentences of each earnings release (8-K item 2.02, exhibit 99), read without AI; results from SEC's XBRL company facts, as first reported.
Also
Earnings releases: each release in full.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ALKS/export.csv") into a cell.